Mulai
Pokethebear

AVEO missed earnings - kidney cancer treatment too thinly traded

Pembelian
Pokethebear Diupdate   
NASDAQ:AVEO   None
Fibonacci Supply and Demand Beyond Technical Analysis oncology kidney pharmaceuticals pharmastocks clinical fullretracement NEW LOW entrypoint
2
0
fibonacci supplyanddemand beyondta oncology kidney pharmaceuticals pharmastocks clinical fullretracement new low entrypoint
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Komentar:
snapshot
Currently at 618fibretracement
Komentar:
Full 241% retracement and bounce to 161%. Sign of bouncing cat?
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.